United States Securities and Exchange Commission

Statement of Changes in Beneficial Ownership

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Hoge Stephen
   C/O Moderna, Inc.
   200 Technology Square
   Cambridge, MA 02139

2. Issuer Name and Ticker or Trading Symbol
   Moderna, Inc. [ MRNA ]

3. Date of Earliest Transaction (Month/Day/Year)
   10/23/2020

4. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person

5. Relationship of Reporting Person(s) to Issuer
   Director
   President

6. If Amendment, Date of Original Filed (Month/Day/Year)

7. Nature of Indirect Beneficial Ownership (Instr. 4)
   By Trust

8. Title and Amount

<table>
<thead>
<tr>
<th>Date Acquired</th>
<th>Code</th>
<th>V</th>
<th>(A)</th>
<th>(D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/23/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>A</td>
<td>$0.99</td>
<td>1,926,530</td>
</tr>
<tr>
<td>10/23/2020</td>
<td>S(1)</td>
<td>7,158</td>
<td>D</td>
<td>$69.52(2)</td>
<td>1,919,372</td>
</tr>
<tr>
<td>10/23/2020</td>
<td>S(1)</td>
<td>7,742</td>
<td>D</td>
<td>$70.47(3)</td>
<td>1,911,630</td>
</tr>
<tr>
<td>10/23/2020</td>
<td>S(1)</td>
<td>100</td>
<td>D</td>
<td>$71.25</td>
<td>1,911,530</td>
</tr>
<tr>
<td>10/23/2020</td>
<td>G</td>
<td>151,933</td>
<td>D</td>
<td>$0</td>
<td>1,759,597</td>
</tr>
<tr>
<td>10/23/2020</td>
<td>G</td>
<td>151,933</td>
<td>A</td>
<td>$0</td>
<td>151,933</td>
</tr>
<tr>
<td>10/26/2020</td>
<td>S(1)</td>
<td>3,000</td>
<td>D</td>
<td>$69.57(4)</td>
<td>1,756,597</td>
</tr>
<tr>
<td>10/26/2020</td>
<td>S(1)</td>
<td>1,700</td>
<td>D</td>
<td>$70.53(5)</td>
<td>1,754,897</td>
</tr>
<tr>
<td>10/26/2020</td>
<td>S(1)</td>
<td>300</td>
<td>D</td>
<td>$71.13(6)</td>
<td>1,754,597</td>
</tr>
<tr>
<td>4,116</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

<table>
<thead>
<tr>
<th>Date Exercisable</th>
<th>Code</th>
<th>V</th>
<th>(A)</th>
<th>(D)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/23/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>(8)</td>
<td>08/19/2023</td>
<td>71.25</td>
<td>Common Stock</td>
<td>10,000</td>
<td>757,431</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.00 to $70.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

4. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.02 to $70.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.00 to $70.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.07 to $71.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

8. This option is fully vested and exercisable.

By: Lori Henderson, as
Attorney-in-Fact
10/27/2020
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.